While some other potential receptors such as Squalene oxide cyclase, FPTase, Leukotriene A4 hydrolase and FKBP, are either conventional clinical targets with anti-tumor effects or target enzymes of drug design; (2) Several receptors identified by two different docking procedures are proposed as best putative targets for four types of catechin; (3) We further explore the binding mode between the most potential receptor Leukotriene A4 hydrolase and EGCG. The gene discussed is LTA4H; the disease is neoplasm.